OSE Immunotherapeutics - Riding the H124 tailwinds
OSE Immunotherapeutics has reported its results for H124, a standout period for the company’s development pipeline, with the momentum carrying into...
342 Views
OSE Immunotherapeutics - Tedopi registrational study commences
OSE Immunotherapeutics has announced the initiation of its Phase III registrational study (Artemia) for lead cancer vaccine Tedopi, with the trial...
500 Views
OSE Immunotherapeutics - Lusvertikimab shines in Phase II UC trial
OSE Immunotherapeutics’ run of positive news continues with the announcement of encouraging data from the Phase II proof-of-concept CoTikiS study,...
441 Views
OSE Immunotherapeutics - Another partnership with expansion into CAR-T
OSE Immunotherapeutics has entered into a commercial and revenue sharing agreement with the Memorial Sloan Kettering Cancer Center (MSK), focused...
360 Views
OSE Immunotherapeutics - Strong momentum in deal flow
OSE Immunotherapeutic’s FY24 has started off with a series of major wins, significantly bolstering the company’s clinical pipeline and liquidity....
335 Views